# Serial Cytology for Treatment Response Assessment in Lymphoma


## Key Takeaways

- Serial lymph node cytology is a practical, minimally invasive, and cost-effective method for assessing treatment response and detecting relapse in canine and feline lymphoma, complementing physical examination.
- Cytologic remission is characterized by a heterogeneous population of small lymphocytes with a normal complement of tingible-body macrophages, while relapse is indicated by a progressive shift towards large or intermediate lymphoid cells and a loss of this mixed population.
- Cytology has limitations in detecting minimal residual disease (MRD) below approximately 1-5% neoplastic cells; for greater sensitivity, molecular techniques like PCR for antigen receptor gene rearrangements (PARR) or flow cytometry are indicated.
- Consistent sampling of the same peripheral lymph node (e.g., mandibular, prescapular, popliteal) at each recheck visit, using a standardized technique and smear preparation, is crucial for accurate serial assessment.
- A four-tier grading system (R0-R3) based on the proportion of large lymphoid cells and overall cellularity provides a framework for clinical decision-making, guiding recheck intervals and treatment adjustments.
- Discrepancies between palpation findings and cytologic results should favor the cytologic interpretation, and in cases of persistent equivocation or suspected composite lymphoma, flow cytometry or histopathology may be necessary for definitive diagnosis and management.

---

Serial lymph node cytology is a practical tool for monitoring response to chemotherapy and detecting relapse in dogs and cats with lymphoma. This article addresses the practicing veterinarian who manages lymphoma patients through multi-agent chemotherapy protocols and needs a defensible framework for deciding when to re-aspirate, how to interpret the findings, and how cytology compares with alternative monitoring strategies. The focus is strictly on treatment response assessment, not initial diagnosis or staging.

Cytology remains the most accessible morphologic method for confirming remission and identifying early recurrence in peripheral lymph nodes. The technique is minimally invasive, inexpensive, and can be performed at every recheck visit without general anesthesia. However, its sensitivity is limited when the burden of residual neoplastic cells is low, and interpretation requires familiarity with post-chemotherapy reactive changes that can mimic or mask disease. Understanding these limitations is essential before building a monitoring protocol.

The clinical question that drives serial cytology is straightforward: does this patient remain in remission, and if not, how early can relapse be detected? Answering that question reliably requires integrating cytologic findings with physical examination, knowing which lymph nodes are most informative, and recognizing when cytology alone is insufficient. This article provides that framework.

## At a Glance

| Parameter | Clinical Decision Point |
|---|---|
| Recheck interval during chemotherapy | Align with each treatment cycle, typically every 1 to 3 weeks depending on protocol |
| Lymph node selection | Aspirate the largest palpable node and any node that is asymmetric, firm, or newly enlarged |
| Cytologic remission criteria | Predominantly small lymphocytes with mixed population, no sheets of large lymphoid cells |
| Relapse criteria | Progressive shift to large or intermediate lymphoid cells, loss of mixed population |
| Palpation versus cytology discrepancy | Cytology overrides palpation when nodes feel normal but cytology shows neoplastic population |
| Minimal residual disease detection | Cytology insensitive below approximately 1 neoplastic cell per 100 to 1000 cells, consider PARR or flow cytometry |
| Indolent lymphoma monitoring | T-zone lymphoma may persist cytologically without clinical progression, correlate with clinical signs |
| Feline cardiac lymphoma | Peripheral lymph node cytology may be normal, suspect extranodal disease if clinical signs progress |

## Rationale for Serial Cytologic Monitoring

The goal of chemotherapy in canine and feline lymphoma is durable remission, not cure in most cases. Clinical remission is defined by resolution of measurable disease, but a residual population of neoplastic cells often persists below the threshold of detection. This population, termed minimal residual disease, is the source of eventual relapse. Cytology and flow cytometry have traditionally been used to detect this residual burden, though both methods lose sensitivity as the malignant cell fraction falls. Molecular techniques such as PCR for antigen receptor gene rearrangements (PARR) with real-time quantitative PCR can detect one neoplastic cell per 10,000 cells, a sensitivity far beyond what cytology can achieve, as described in work on minimal residual disease in canine lymphoma from the University of Tokyo group.

Despite this sensitivity gap, cytology retains a central role because it is rapid, inexpensive, and does not require baseline clonal rearrangement data. A well-prepared lymph node aspirate can confirm remission, document relapse, or flag equivocal findings that warrant more sensitive testing. Serial sampling also provides a longitudinal record of each patient's cytologic pattern, which can be valuable when a node changes character between visits.

The European canine lymphoma group has emphasized the value of cytology and flow cytometry as tools for diagnosis, disease progression monitoring, and prognosis. Their workshop proceedings highlight that cytology is also a diagnostic adjunct but a monitoring modality in its own right, particularly when combined with clinical assessment at each treatment visit.

## Cytologic Features of Remission

A lymph node in cytologic remission should show a heterogeneous population of small lymphocytes, with fewer intermediate and large lymphocytes, and a normal complement of tingible-body macrophages. The architecture is not preserved in aspirates, so assessment relies on population composition instead of follicular structure. The key feature is the absence of sheets or clusters of large lymphoid cells with prominent nucleoli and basophilic cytoplasm.

Post-chemotherapy nodes may show reactive hyperplasia, with increased numbers of medium and large lymphocytes, plasma cells, and macrophages. This pattern can be difficult to distinguish from residual neoplasia, particularly in high-grade lymphomas where the neoplastic population is composed of large cells. The distinction rests on whether the large cells are admixed with a diverse population or present as a monomorphic expansion. A monomorphic population of large lymphoid cells, regardless of absolute number, should be considered suspicious for persistent or recurrent disease.

## Cytologic Features of Relapse

Relapse is characterized by a progressive loss of the mixed lymphoid population and re-emergence of a monomorphic neoplastic cell type. The cytologic pattern usually recapitulates the original diagnosis, so comparison with the initial aspirate is essential. A node that previously showed large granular lymphocytes will relapse with the same morphology in most cases, though phenotypic shift or transformation to a higher grade can occur.

The timing of relapse detection depends on sampling frequency and the growth rate of the neoplastic clone. Slowly progressive relapses may be detected at routine recheck visits before clinical signs develop. Rapidly progressive disease can become clinically apparent between scheduled visits, and cytology then confirms what palpation already suggested. Serial sampling at each chemotherapy visit provides the best chance of detecting relapse at the earliest feasible time point.

## Limitations of Cytology in the Remission Setting

Cytology cannot reliably exclude the presence of a small residual neoplastic population. When the malignant cell fraction falls below roughly 1 to 5 percent of the total lymphoid population, morphologic identification becomes unreliable. This is the minimal residual disease window, where molecular methods such as allele-specific real-time quantitative PCR offer substantially greater sensitivity.

A second limitation is sampling error. A single aspirate samples a tiny fraction of a lymph node, and early relapse may be focal. Aspirating multiple nodes or multiple sites within one enlarged node reduces but does not eliminate this risk. Nodes that are small and difficult to palpate may yield scant cellularity, making interpretation impossible. In such cases, the aspirate should be reported as nondiagnostic instead of interpreted as remission.

Flow cytometry can complement cytology by detecting aberrant immunophenotypes, such as loss of CD45 expression in T-zone lymphoma, even when the morphologic features are subtle. A case report describing concurrent T-zone lymphoma and B-cell lymphoma in a dog demonstrated that serial flow cytometry could document complete remission of one neoplastic population while the other persisted, a distinction that cytology alone could not reliably make.

## Sampling Technique and Site Selection for Serial Rechecks

The quality of serial cytology depends on consistent sampling of the same node at each recheck. Peripheral lymph nodes are preferred because they are accessible, and the mandibular, prescapular, and popliteal nodes are most commonly sampled. The popliteal node is often selected for serial monitoring because it is easy to immobilise, but any consistently palpable node will suffice. Mark the chosen node in the medical record, including laterality, so that subsequent aspirates target the same site. Different nodes within the same animal can show divergent cytologic findings, particularly in dogs with multicentric disease, and sampling a different node at each visit introduces a variable that can confound response assessment.

Fine-needle aspiration with a 22 to 25 gauge needle is standard. Capillary action sampling without suction typically yields adequate cellularity for lymphoid assessment and causes less hemodilution than aspiration with a syringe. For small or poorly exfoliative nodes, suction may be required, but the operator should recognize that blood contamination can dilute the lymphoid population and obscure a low-grade infiltrate. Smear preparation should be consistent: a single gentle squash preparation or a blood-smear technique produces a monolayer that preserves nuclear detail. Thick, crushed, or overly bloody preparations should be repeated before the patient leaves the examination room, because a non-diagnostic sample cannot be interpreted and forces the clinician to choose between repeating the aspirate and making a treatment decision on inadequate data.

Sedation is rarely required for peripheral lymph node aspiration in dogs and cats. A calm, well-restrained patient can usually be sampled without chemical restraint, and the procedure is brief. Severely anxious patients or those with deeply seated nodes may benefit from low-dose sedation, but this should be weighed against the frequency of rechecks in a chemotherapy protocol. Repeated sedation adds cost and time to every visit and may reduce owner compliance with the monitoring schedule.

## A Cytologic Grading System for Treatment Response

Serial cytology is most useful when each sample is assigned a grade that can be tracked over time. A four-tier grading system based on the proportion of large lymphoid cells and the overall cellular population provides a practical framework for clinical decision-making. The grade is assigned after scanning the monolayer at low power and confirming the dominant population at high power.

| Grade | Cytologic Description | Clinical Interpretation |
|-------|----------------------|------------------------|
| R0 | Predominantly small lymphocytes, no significant population of large lymphoid cells, mixed population with tingible-body macrophages | Complete remission by cytology |
| R1 | Mixed population with scattered large lymphoid cells, but small lymphocytes remain the majority | Consistent with remission, borderline findings warrant closer recheck |
| R2 | Large lymphoid cells form a substantial minority or codominant population, residual small lymphocytes still present | Suspicious for early relapse, repeat aspirate in 2 to 3 weeks or pursue ancillary testing |
| R3 | Monomorphic population of large lymphoid cells, small lymphocytes are sparse or absent | Cytologic relapse, confirm and adjust therapy |

The R0 grade corresponds to the expected post-treatment appearance of a reactive or depleted node. A heterogeneous population of small lymphocytes, intermediate cells, plasma cells, and tingible-body macrophages indicates an ongoing immune response instead of residual neoplasia. The R1 grade is the most challenging to interpret. A few large lymphoid cells can appear during recovery from chemotherapy, and their presence alone does not establish relapse. The trend matters more than any single sample: an R1 that follows an R0 and progresses to R2 on the next recheck is far more concerning than a stable R1 that persists across several visits.

The R2 grade should trigger a shorter recheck interval. If the patient is still receiving maintenance chemotherapy, the clinician may choose to continue the current protocol and recheck cytology in 2 to 3 weeks. If the patient has completed therapy, an R2 sample warrants a repeat aspirate sooner, because early intervention at relapse may improve the chance of reinduction. The R3 grade represents cytologic relapse. In most cases this finding is accompanied by palpable lymphadenomegaly, but cytology can detect relapse before the node enlarges, and the grade should be recorded regardless of node size.

## Recheck Schedule and Integration with Clinical Assessment

The recheck schedule should be structured around the treatment protocol and the patient's risk profile. During induction chemotherapy, cytologic assessment is typically performed at each treatment visit or at every other visit. This frequency captures the response trajectory and identifies primary resistance early. Once complete remission is confirmed by cytology, the interval can be extended. A common schedule is monthly rechecks during the first three months of remission, then every two to three months thereafter. The European canine lymphoma group has emphasized the value of cytology for disease progression monitoring, and serial sampling at defined intervals is the practical expression of that principle.

Each recheck should combine cytology with a complete physical examination. Lymph node size is assessed by palpation and recorded using a consistent scheme, such as the longest diameter or a subjective scale. The correlation between palpation and cytology is imperfect. A node that feels normal may harbour a monomorphic population of large cells, and a node that feels enlarged may show only reactive hyperplasia. The clinician should act on the cytologic grade instead of the palpation finding when they conflict. In one retrospective study, a serum biomarker panel was compared with clinicians' assessment using palpation and cytology, and the biomarker approach detected recurrence before lymphadenopathy appeared. This finding underscores that clinical examination alone can miss early relapse, and cytology provides a more sensitive assessment of the lymph node compartment.

Flow cytometry can complement serial cytology in selected cases. A dog with concurrent T-zone lymphoma and B-cell lymphoma was monitored with serial flow cytometry, which demonstrated complete remission of the neoplastic B cells while the neoplastic T cells persisted. Cytology alone could not have distinguished these two populations, and the treatment decision depended on knowing which clone was responding. When flow cytometry is available and the immunophenotype is known, serial flow cytometric monitoring can be added to the cytologic schedule, particularly for patients with suspected composite lymphoma or an indolent component.

## Documentation and Communication of Serial Findings

Serial cytology generates a longitudinal record that is only useful if it is documented consistently. Each entry should include the date, the node sampled, the sample quality, the cytologic grade, and a brief description of the dominant population. Photomicrographs of representative fields are valuable for retrospective comparison, particularly when a new clinician or pathologist reviews the case. The medical record should also note the clinical context: current chemotherapy protocol, time since last treatment, and any concurrent illness that could affect the node.

The cytologic grade should be communicated to the owner in terms that support the treatment plan. Owners often interpret lymph node enlargement as immediate relapse, and a cytologic finding of reactive hyperplasia can provide reassurance that the node is responding to inflammation or vaccination instead of neoplasia. Conversely, an R3 grade should be presented as a finding that requires confirmation and a treatment decision, not as an immediate prognosis. The distinction between cytologic relapse and clinical relapse matters: cytology can detect disease before it is clinically apparent, and the owner should understand that early detection creates an opportunity for intervention.

## Species-Specific Considerations

The grading system and recheck schedule apply to both dogs and cats, but the underlying biology differs. Feline lymphoma is more often extranodal, and peripheral lymph node cytology may not reflect disease burden in the gastrointestinal tract or other sites. A cat with alimentary lymphoma can be in cytologic remission in the peripheral nodes while progressive disease continues in the intestine. Serial cytology in cats is therefore most informative when the sampled node is known to be involved at diagnosis, and the limitations of peripheral sampling should be acknowledged in the medical record.

Indolent lymphomas present a particular challenge. T-zone lymphoma in dogs can produce persistent lymphadenopathy that does not respond to chemotherapy in the same way as high-grade disease. Serial cytology in these patients may show a stable population of neoplastic cells that never reaches an R0 grade, and the clinician must interpret the grade in the context of the known immunophenotype and clinical behavior. A stable R2 in a dog with T-zone lymphoma may represent acceptable disease control, whereas the same grade in a dog with diffuse large B-cell lymphoma would prompt immediate action. The cytologic grade is a tool, not a verdict, and it must be interpreted within the full clinical picture.

## Recognized Complications and Failure Modes

Serial cytology fails as a monitoring tool when sampling, preparation, or interpretation introduces error that mimics or masks disease progression. The most consequential failure is a false-negative aspirate during suspected relapse. A single needle pass through a partially effaced node can harvest only residual small lymphocytes, producing a sample that looks reactive while the remainder of the node contains neoplastic large cells. This sampling error is more likely when nodes are small, fibrotic, or heterogeneous after chemotherapy. The discriminating check is repeat aspiration from multiple sites within the node and, when feasible, from multiple nodes. If clinical suspicion remains high despite a benign cytologic appearance, proceed to flow cytometry or histopathology instead of accepting the cytologic result at face value.

A second failure mode is over-interpretation of mildly atypical lymphoid populations during remission. Post-chemotherapy nodes frequently contain intermediate-sized lymphocytes, tingible-body macrophages, and scattered large cells that can resemble residual neoplasia. The corrective action is to apply a consistent grading system across serial samples and to interpret any single sample in the context of the trend, not in isolation. A stable or declining atypical population supports remission, whereas progressive loss of small lymphocytes and increasing large-cell proportion favours relapse.

Drying artefact and hemodilution are preparation failures that render samples non-diagnostic. Blood contamination dilutes the lymphoid population and can obscure the true cell proportions. Thick smears with overlapping cells prevent accurate nuclear assessment. The corrective action is to prepare multiple slides at each visit, stain promptly, and reject non-diagnostic samples before interpretation. A cytology report based on an inadequate sample is worse than no report, because it creates false confidence.

## Common Errors and Corrective Actions

Less experienced clinicians often equate the presence of any large lymphoid cells with relapse. Large cells appear in reactive nodes, particularly after vaccination or during inflammation, and their proportion matters more than their presence. The corrective action is to quantify the large-cell fraction relative to small lymphocytes and to require a progressive increase across serial samples before diagnosing relapse.

A related error is sampling only the largest palpable node. The largest node may be the most fibrotic or necrotic and can yield misleadingly hypocellular aspirates. Sample multiple nodes at each recheck and record which node was sampled so that serial comparisons are made within the same node when possible.

Students and new graduates frequently omit clinical correlation. A cytologic sample that suggests relapse in a dog with no palpable lymphadenopathy and normal appetite warrants a different response than the same sample in a dog with progressive lymphadenopathy and systemic signs. The corrective action is to record physical examination findings, body weight, and owner-reported signs at each recheck and to interpret cytology within that framework. The [European canine lymphoma group workshop report](https://pubmed.ncbi.nlm.nih.gov/24193915/) emphasized the combined value of cytology and flow cytometry for disease progression monitoring, and this combined approach becomes increasingly important when cytologic findings and clinical assessment diverge.

## Evidence Limitations and Divergent Expert Opinion

The evidence base for serial cytology in lymphoma monitoring rests largely on retrospective studies and expert consensus instead of prospective trials. Cytology has recognized sensitivity limits for detecting minimal residual disease, as discussed in the [review of minimal residual disease markers in canine lymphoma](https://pubmed.ncbi.nlm.nih.gov/27339366/), and a cytologically normal node does not exclude the presence of a small neoplastic clone. Molecular methods such as PCR for antigen receptor gene rearrangements can detect one neoplastic cell in 10,000 normal cells, a sensitivity that cytology cannot approach.

Expert opinion differs on how aggressively to pursue suspected relapse. Some clinicians re-aspirate at 2 to 3 week intervals when cytology is equivocal, while others proceed directly to flow cytometry or histopathology. The [case report describing concurrent T-zone lymphoma and B-cell lymphoma](https://pubmed.ncbi.nlm.nih.gov/34176384/) illustrates a specific limitation: cytology and even flow cytometry can miss a second neoplastic population, and persistent lymphadenopathy after apparent remission of one clone warrants investigation for a concurrent process. There is no consensus on the optimal frequency of cytologic monitoring after remission is achieved, and practice varies from monthly to every 3 months.

## Escalation and Referral Criteria

Referral or specialist consultation is warranted when cytologic findings are persistently equivocal despite adequate samples, when clinical progression and cytology disagree, or when a second neoplastic population is suspected. Flow cytometry adds immunophenotypic information that cytology cannot provide, particularly for detecting aberrant antigen expression and distinguishing reactive from neoplastic populations. The [case of high-grade T-cell lymphoma initially suspected to be indolent](https://pubmed.ncbi.nlm.nih.gov/30229963/) demonstrates that cytology alone can misclassify disease behavior, and histopathology or flow cytometry should be pursued when the cytologic grade and clinical course are discordant.

Laboratory involvement is appropriate when sample quality is repeatedly poor, when the laboratory's reference intervals or grading criteria are unclear, or when a second opinion on difficult slides would change management. Regulatory reporting is not typically required for lymphoma monitoring in companion animals, but clinicians should be aware that [WOAH terrestrial animal health standards](https://www.woah.org/en/what-we-do/standards/codes-and-manuals/terrestrial-code-online-access/) may apply if a jurisdiction requires notification of neoplastic disease in specific contexts, such as export certification or food-producing species.

| Observation | Likely cause | Discriminating check |
|---|---|---|
| Benign cytology with progressive lymphadenopathy | Sampling error, concurrent second neoplasm | Repeat aspirates from multiple sites, flow cytometry, histopathology |
| Atypical large cells on one sample, no progression on next | Reactive population, sampling variation | Repeat sampling at short interval, compare proportions across samples |
| Hypocellular or hemodilute sample | Fibrosis, necrosis, poor technique | Re-aspirate, prepare fresh slides, sample a different node |
| Persistent lymphadenopathy with cytologic remission | Second neoplastic population, residual fibrosis | Flow cytometry, histopathology, consider clonality testing |
| Cytologic relapse without clinical signs | Early relapse, indolent disease | Short-interval recheck, stage with imaging and blood work |

## Frequently Asked Questions

### How Should I Adjust Serial Cytology When Cost or Client Resources Are Limited?

When financial constraints limit recheck frequency, prioritize cytology at the timepoints with the highest diagnostic yield: at the end of induction to confirm remission, and at the first suspicion of relapse based on palpation or clinical signs. Between those points, physical examination by the same clinician provides a reproducible baseline. If a node becomes palpably enlarged, aspirate it immediately instead of waiting for the scheduled recheck. Serum biomarkers such as haptoglobin and C-reactive protein, combined in a multivariate algorithm, have shown reasonable agreement with clinician assessment of remission and recurrence in dogs, and may serve as a less invasive adjunct when cytology is not affordable. Document the reduced monitoring intensity in the medical record so response assessment criteria remain transparent.

### What Can I Do When High-Quality Cytology Smears Are Not Possible in the Clinic?

Poor smear quality compromises grading accuracy more than any other technical factor. If you cannot obtain a well-spread, thinly feathered smear, request assistance from a colleague with more aspiration experience or consider an alternative collection method such as a non-aspiration capillary technique. When slide preparation remains suboptimal, submit the sample to a commercial laboratory with a clinical pathologist instead of attempting interpretation in-house. The [ASVCP quality assurance guidelines](https://www.asvcp.org/page/QALS_Guidelines) address sample handling and submission standards that apply to cytologic specimens. If a node is too small or mobile to aspirate reliably, ultrasound guidance improves targeting. Do not substitute a single poor-quality slide for a proper assessment, repeat the aspiration at the same visit if necessary.

### How Does Serial Cytology Monitoring Differ in Cats Compared with Dogs?

Feline lymphoma presents more frequently at extranodal sites, including the gastrointestinal tract, mediastinum, and nasal cavity, where peripheral lymph node cytology is not a reliable monitoring target. For cats with peripheral nodal disease, the same cytologic criteria for remission and relapse apply, but the kinetics of disease may differ. Indolent phenotypes such as T-zone lymphoma in dogs can persist with stable cytologic abnormalities for extended periods, and this pattern has also been described in feline cases. In cats, concurrent diseases such as inflammatory bowel disease or chronic infections can cause reactive lymphoid hyperplasia that mimics residual neoplasia cytologically. The [MSD Veterinary Manual](https://www.msdvetmanual.com/) provides species-specific guidance on lymphoma presentation and monitoring. When cytology is equivocal in a cat, flow cytometry or PCR-based clonality testing may be needed to distinguish reactive from neoplastic populations.

### What Is the Role of Flow Cytometry When Serial Cytology Is Equivocal?

Flow cytometry complements cytology by providing objective immunophenotypic data and detecting aberrant antigen expression that cytology cannot assess. In one reported case, serial flow cytometric analysis demonstrated complete remission of a neoplastic B-cell population while a concurrent T-zone lymphoma population persisted, a distinction that cytology alone could not reliably make. Flow cytometry is particularly valuable when cytology shows a mixed or atypical lymphoid population, when relapse is suspected but cytologic features are ambiguous, or when monitoring known concurrent neoplasms. The technique requires fresh samples and specialised laboratory access, which limits its use in general practice. For most patients, cytology remains the first-line monitoring tool, with flow cytometry reserved for cases where cytologic interpretation will change the treatment decision.

### How Should I Document Serial Cytology Findings in the Medical Record?

Record each aspiration as a separate entry with the date, node sampled, collection method, smear quality, and a descriptive cytologic interpretation instead of a single-word diagnosis. Include a semiquantitative estimate of the large-cell or intermediate-cell proportion, mitotic figures, and background features such as tingible-body macrophages. Note the clinical lymph node size at the time of sampling so cytology and palpation can be correlated. If a grading system is used, record the numeric grade and the criteria that determined it. Serial entries should be structured so that trends are visible at a glance, for example by using a consistent format for each recheck. This documentation supports treatment decisions, client communication, and referral if the case escalates.

### How Do I Explain Serial Cytology Results to a Client Whose Pet Is in Remission?

Explain that remission means the lymph nodes look normal or near-normal under the microscope, but that a small number of lymphoma cells may remain below the detection limit of cytology. This residual population, termed minimal residual disease, is the reason relapse can occur months after remission is achieved. Cytology at each recheck provides a snapshot of whether the cell population is stable, improving, or shifting toward a more immature appearance. Emphasize that a single normal aspirate does not guarantee cure, and that the value of serial monitoring lies in detecting change early, when intervention may be more effective. Reassure the client that cytology is minimally invasive and that the findings guide whether treatment continues unchanged or requires adjustment.

## Related Clinical & Scientific Guides

* [Peripheral Blood Smear Evaluation: A Step-by-Step Guide](/knowledge/veterinary-medicine/clinical-pathology/peripheral-blood-smear-evaluation-guide)
* [Reticulocyte Counts in Veterinary Medicine: Clinical Utility and Interpretation](/knowledge/veterinary-medicine/clinical-pathology/reticulocyte-counts-veterinary-medicine)
* [Cerebrospinal Fluid Analysis in Veterinary Neurology: Collection and Interpretation](/knowledge/veterinary-medicine/clinical-pathology/cerebrospinal-fluid-analysis-veterinary)


## References and Further Reading

- [Utility of a multiple serum biomarker test to monitor remission status and relapse in dogs with lymphoma undergoing treatment with chemotherapy.](https://pubmed.ncbi.nlm.nih.gov/25319380/). 2017.
- [Minimal residual disease in canine lymphoma: An objective marker to assess tumor cell burden in remission.](https://pubmed.ncbi.nlm.nih.gov/27339366/). 2016.
- [First meeting of the European canine lymphoma group. Workshop: state of the art and comparative aspects in canine lymphoma. CH-Lugano, 22 June 2013.](https://pubmed.ncbi.nlm.nih.gov/24193915/). 2014.
- [A case of canine high-grade T-cell lymphoma immunophenotypically consistent with T-zone lymphoma.](https://pubmed.ncbi.nlm.nih.gov/30229963/). 2018.
- [Clinical signs associated with severe ST segment elevation in three cats with a hypertrophic cardiomyopathy phenotype.](https://pubmed.ncbi.nlm.nih.gov/39004067/). 2024.
- [Monitoring of large B-cell lymphoma and T-zone lymphoma in a dog via flow cytometry.](https://pubmed.ncbi.nlm.nih.gov/34176384/). 2021.
- [American Society for Veterinary Clinical Pathology Guidelines](https://www.asvcp.org/page/QALS_Guidelines). American Society for Veterinary Clinical Pathology.
- [MSD Veterinary Manual, Professional Edition](https://www.msdvetmanual.com/). MSD Veterinary Manual.
- [American Veterinary Medical Association Practice Resources](https://www.avma.org/resources-tools). American Veterinary Medical Association.

## Related Articles

- [Laboratory Monitoring of Anemia: Reticulocyte Response and Beyond](/knowledge/veterinary-medicine/clinical-pathology/laboratory-monitoring-anemia-reticulocyte)
- [Monitoring Cortisol Levels During Treatment of Hyperadrenocorticism](/knowledge/veterinary-medicine/clinical-pathology/monitoring-cortisol-levels-treatment-hyperadrenocorticism)
- [Serial Coagulation Monitoring in Veterinary Patients: Indications and Interpretation](/knowledge/veterinary-medicine/clinical-pathology/serial-coagulation-monitoring-veterinary-patients-indications-interpretation)
- [Serial Urinalysis in Monitoring Urinary Tract Infections](/knowledge/veterinary-medicine/clinical-pathology/serial-urinalysis-monitoring-urinary-tract-infections)
- [Monitoring Thyroid Hormone Levels During Treatment of Hypothyroidism](/knowledge/veterinary-medicine/clinical-pathology/monitoring-thyroid-hormone-levels-treatment-hypothyroidism)

> This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.